arrow
S

Sang-Bing Tsai

International Engineering and Technology Institute
H指数:49
被引数:8,456

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

CAR HEMATOTOX 独立预测急性淋巴细胞白血病接受CD19 CAR-T疗法后的结局

2025-10-080
OAAI
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis

评估异质性结局驱动因素及风险分层在骨髓纤维化患者队列中的适用性

2025-10-060
OA
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

社会决定因素对成人复发/难治性B细胞急性淋巴细胞白血病患者brexucabtagene autoleucel治疗结局的影响

2025-08-230
OAAI
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Brexucabtagene autoleucel在伴有CNS受累的复发/难治性急性淋巴细胞白血病患者中的疗效

2025-05-090
OAAI
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
2024-12-102
OAAI
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Brexucabtagene autoleucel治疗60岁及以上患者复发/难治性B细胞急性淋巴细胞白血病的有效性与安全性

BLOOD
IF23.1
2024-11-051
PRE
Association of Neighborhood Crime with AML Molecular Subtypes and Survival

社区犯罪与AML分子亚型及生存期的关联

BLOOD
IF23.1
2024-11-050
PRE